🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Lifecore Biomedical revises past financial statements

EditorEmilio Ghigini
Published 03/20/2024, 07:29 AM
© Reuters.
LFCR
-

CHASKA, Minn. - Lifecore Biomedical, Inc. (NASDAQ: LFCR), a contract development and manufacturing organization, has filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023, with the Securities and Exchange Commission (SEC), which includes a restatement of its financials for previous years. The restatements correct errors in capitalized interest calculations, inventory valuations, and adjustments related to divested businesses.

The restatements primarily affect the financial statements for the fiscal years ended May 29, 2022, and May 30, 2021. Key adjustments include writedowns of inventory to net realizable value, recording of reserves for excess and obsolete inventories, recording of capitalized interest on assets under construction, and adjustments to revenues and costs of sales for certain performance obligations. Additionally, an accounts receivable reserve was recorded for a specific customer.

The company's former Curation Foods segment also underwent restatements, including adjustments to non-current other receivables and the presentation of certain operating costs and expenses of continuing and discontinued operations.

To aid investors, Lifecore has provided a supplementary summary of select financial data related to its ongoing Lifecore business. This supplementary financial data is available in the Investors section of the Lifecore website.

Lifecore Biomedical specializes in the development, fill, and finish of complex sterile injectable pharmaceutical products. With over 40 years of experience, the company partners with biopharmaceutical and biotechnology companies to bring their products to market.

The press release also contains forward-looking statements, including the company's ability to become current with its SEC reports, regain compliance with Nasdaq listing standards, and expand relationships with existing customers. These statements are subject to risks and uncertainties that could cause actual results to differ materially.

This news is based on a press release statement from Lifecore Biomedical, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.